The identification of ALK translocation in NSCLC was reported for the first time in 2007, when in some preclinical models it was demonstrated that the chemical inhibition of ALK fusion protein led to a dramatic reduction in tumor cell growth and to a significant survival advantage of ALK-positive lung cancer murine xenografts [72]. Here, ALK is linked to non-small cell lung carcinoma.